DP、EP化疗方案治疗非小细胞肺癌的临床疗效及其对血清血管内皮生长因子的影响  

Contrastive Analysis on the Clinical Effects and Safety of DP and EP in Treating Non-Small Cell Lung Cancer and Its Influence on Serum VEGF Level

作　　者：孙琦[1] 方宏娇[1] 吕杨[1] 姜庆玲[1] 

机构地区：[1]中国人民解放军海军安庆医院肿瘤内科,安庆246003

出　　处：《成都医学院学报》2013年第3期297-299,共3页Journal of Chengdu Medical College

基　　金：中国高校医学期刊临床专项资金项目(NO:11321022)

摘　　要：目的对比DP、EP化疗方案治疗非小细胞肺癌(NSCLC)的临床疗效及其对血清血管内皮生长因子(VEGF)的影响。方法 102例晚期NSCLC患者随机分为DP组(n=58)和EP组(n=44)。DP组静脉注射多西紫杉醇75mg/m2,d1;静脉滴注顺铂75mg/m2,d1～4;EP组静脉滴注依托泊苷0.1g/d,d1～5;顺铂用法同上。两组28d为1个周期,治疗3个周期,化疗前后常规给予止呕类药物及对症治疗。检测两组临床疗效和血清VEGF水平。结果 DP组、EP组,总有效率分别为74.14%和29.55%,DP组总有效率明显高于EP组。与治疗前比较,两组治疗后血清VEGF水平均明显降低。DP组治疗后血清VEGF水平明显低于EP组治疗后。结论 DP治疗中晚期NSCLC临床疗效确切,有效率、生存率均较高。Objective To contrastively analyze the clinical effects and safety of DP and EP in treating non- small cell lung cancer （NSCLC） and its influence on serum VEGF level. Methods One hundred and two patients with advanced NSCLC were randomly divided into DP group （n=58） and EP group （n= 44）. The former was intravenously injected with 75 mg/m2 docetaxel on the first day and 75 mg/m2 cisplatinum on d1-4 ,while the latter was additionally injected with 0.1 g/d etoposide on d1-5. Took 28 days as one course of treatment,and 3 courses were treated for both groups. Anti-nausea drugs and symptomatic treatments were also given before and after treatment for the both groups. Clinical effects and serum VEGF level in two groups were observed. Results The total effective rate of DP group （74.14%） was evidently higher than that of EP group （29.55%）. The serum VEGF levels in both groups decreased remarkably after treatment, however, the serum VEGF level in DP group was obviously lower than that in EP group. Conclusion DP is a highly effective and safe method in treating NSCLC, with high survival rates.

关 键 词：非小细胞肺癌 多西紫杉醇 依托泊苷 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤]